hero image

BIOGEN PUBLISHES 2022 ESG REPORT

May 1, 2023 Company Statements

Biogen has published its 2022 ESG Report, which supports Biogen’s business goals by sharing our corporate responsibility story, disclosing key environmental, social, and governance (ESG) data and providing updated progress against our targets and commitments. You can find a copy here.  

Biogen Safe Harbor
This statement includes forward-looking statements based on our current expectations and beliefs that are subject to risks and uncertainties. Our actual results may differ materially. Please consult the risk factors section of our SEC filings.

 

thumb
April 25, 2024
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA ® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human

thumb
April 24, 2024
Biogen Reports First Quarter 2024 Results